Book an Appointment for COVID-19 Testing





New at Atlas


What is HART testing?

HART CVE is a simple, highly accurate blood test for scoring your risk for a heart attack, stroke or cardiac death. Developed and validated in collaboration with renowned researchers at Massachusetts General Hospital, HART CVE proved to be more accurate (86%) than other available tests, including genetic and stress tests (53%).2,3

Speak to us about HART Testing!



Heart Disease
Know the Facts 1



Heart disease is the
leading cause of death
in the U.S.—1 in 3 deaths.

Heart disease is 80% preventable.

50% of heart attack patients have
normal cholesterol.


HART Testing
An Inside Look

Prevencio’s HART technology delivers an overall risk score, along with a more detailed breakdown of risk factors.


HART CVE Score



A score from 0 – 3 indicates a lower likelihood of developing a heart event; specifically, a less than 1% risk of having a heart attack, stroke, or cardiovascular death within 1 year.


A score of 4 – 6 signifies a moderate likelihood of developing a heart event; specifically, a less than 7% risk of having a heart attack, stroke, or cardiovascular death within 1 year.


A score of 7 – 10 indicates a higher likelihood of developing a heart event; specifically, a greater than 20% risk of having a heart attack, stroke, or cardiovascular death within 1 year.






ATLAS Genomics is a CLIA-certified high complexity molecular diagnostic laboratory in Seattle, WA.

Our mission is to provide the highest quality testing, service, and technology as the physician’s top choice molecular specialty lab. We use Next-Generation Sequencing technology from Illumina® to provide the most current diagnostics testing services to the physician, with a focus on patient outcomes, physician-friendly reports and process, and the highest level of personal service for the clinic.

Next-Generation Accuracy


Physician Centered Reports


Expert Support for Your Clinic

Wide range of testing we offer


Ashkenazi Jewish Screening

CMX Panel

NIPT (Non-Invasive Prenatal Testing)

COVID-19 Testing

Atlas Express Panel

UTI (Urinary Tract Infection) Screening

Carrier Screening

Antibiotic Resistance Testing

Women’s Health Screening


Dr. Kalnoski

Our Leader


Michael H. Kalnoski is a physician triple-board-certified in Anatomic Pathology, Clinical Pathology, and Hematology. He attended graduate school at UCLA in cell and molecular biology and later took MBA classes in San Francisco and St. Louis before graduating from Medical School at St. Louis University School of Medicine. He completed his residency (AP/CP) and fellowship (Hematology) at the University of Washington. Enjoying his life and the community in Seattle, he decided to open up his own laboratory right here, Atlas Genomics. Dr. Kalnoski has built many labs, including The National Reference Laboratory, which received both College of American Pathology and ISO-15189 certification in the same year (one of only 7 labs to achieve dual accreditation). Outside the lab, Dr. K enjoys snow skiing, hiking, biking, and boating.


Meet Our Dedicated Team


References
1. Heart Disease Facts | cdc.gov
2. McCarthy, CP, Januzzi, JL, et al. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study).
Am J Cardio l 2017; 120(1):25-32.
3. Neumann JT, Januzzi JL, Westermann D. et al. Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction.
Biomark Med. 2020 Jun;14(9):775-784.
doi: 10.2217/bmm-2019-0584.
Epub 2020 May 28. PMID: 32462911.

© 2020 Atlas Genomics. All rights reserved.